Dr. Amanda L. Cantor, MD
Pediatric Gastroenterology (Pediatric Transplant Hepatology Physician)
At a glance
- Years since graduation
- 10
- In the NPI registry since
- 2016
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Transplant Hepatology Physician primary
NY license 299764 -
Pediatric Gastroenterology Physician
NY license 299764
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 4 companies reported 16 payments worth $766 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $505 |
|---|---|
| Mirum Pharmaceuticals, Inc. | $132 |
| Madrigal Pharmaceuticals | $98.22 |
| Orphalan Inc | $30.61 |
| Food and Beverage | $766 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $29,153 in research payments for these studies, mostly to the institutions running them.
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
Albireo Pharma, Inc. · Active, not recruiting · NCT05426733 - Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
Albireo Pharma, Inc. · Completed · NCT04336722
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.